The practical significance of using Canephron N medication for radiation cystitis prevention in patients undergoing radiation/chemoradiation therapy

Background. With increasing life expectancy in cervical cancer patients, new medical and social problems associated with radiation therapy become apparent.  The combination of radiation therapy and chemotherapy is an important therapeutic component in treatment of malignant neoplasms of the genital area in women, but the frequency and severity of side effects has been increasing. Radiation complications occur in 20–50 % of patients.  In 5 % of patients, they can represent a severe and potentially life-threatening condition. Prevention of negative effects on the genitourinary system in cervical cancer patients receiving radiation therapy on the pelvis is a matter of importance.

Aim. To evaluate the clinical efficacy of a phytotherapeutic  preparation Canephron  N containing centaury, lovage root, rosemary leaves in the prevention of radiation cystitis during chemoradiotherapy in patients with advanced cervical cancer.

Materials and methods. The study included 60 patients with locally advanced cervical cancer receiving radical chemoradiotherapy. The patients were divided into 2 groups: treatment  group consisting of patients receiving phytotherapeutic preparation Canephron N for prevention of radiation complications, and control group consisting of patients not receiving symptomatic treatment.  The treatment results were evaluated using questionnaires, clinical, laboratory and instrumental studies. The obtained data were compared with the results of treatment of the control group which were not prescribed a medication for prevention of urological complications.

Results and conclusion. The use of Canephron N in accompanying therapy had significantly decreased the risk and incidence of radiation cystitis.

1. Berdichevskiy V.B., Berdichevskiy B.A., Bespalova T.V., Chibulaeva E.V. Analysis of nephrological morbidity based on results of the organized population medical examination. Meditsinskaya nauka i obrazovanie Urala = Medical Science and Education in the Urals 2018;(4): 126–8. (In Russ.).

2. Zharinov G.M., Vinokurov V.L., Zaikin G.V. Radiation injuries of the rectum and bladder in patients with cervical cancer. Mir meditsiny = World of Medicine 2000;(7–8):12–4. (In Russ.).

3. Gordeev S.S., Ivanov V.A., Rasulov A.O. et al. Chemoradiation therapy for complicated locally advanced and recurrent rectal cancer. Meditsinskaya radiologiya i radiatsionnaya bezopasnost = Medical Radiology and Radiation Safety 2016;61(6):57–63. (In Russ.).

4. Delaney G., Jacob S., Barton M. Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part I – malignancies of the cervix, ovary, vagina and vulva. Cancer 2004;101(4):671–81. DOI: 10.1002/cncr.20444

5. Mendenhall W.M., Henderson R.H., Costa J.A. et al. Hemorrhagic radiation cystitis. Am J Clin Oncol 2015;38(3):331–6. DOI: 10.1097/COC.0000000000000016

6. Kaprin V.A. Theoretical scheme of chronic pathological process. Rossiyskiy meditsinskiy zhurnal = Russian Medicine 2006;(2):50–2. (In Russ.).

7. Zwaans B.M.M., Lamb L.E., Bartolone S. et al. Cancer survivorship issues with radiation and hemorrhagic cystitis in gynecological malignancies. Int Urol Nephrol 2018;50(10):1745–51. DOI: 10.1007/s11255-018-1970-2

8. Streltsova O.S., Krupin V.N. Microcirculation in the bladder “hot spots” in radiation cystitis. Proceedings of the International Multidisciplinary Symposium “Chronic Pelvic Pain”. Nizhny Novgorod, June 16–17 2008. Pp. 21–23. (In Russ.).

9. Ceradini D.J., Kulkarni H., Callaghan M.J. et al. Progenitor cell/ trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF. Nat Med 2004;10(8):858–64. DOI: 10.1038/nm1075

10. Ma J.L., Hennessey D.B., Newell B.P. et al. Radiotherapy-related complications presenting to a urology department: a more common problem than previously thought? BJU Int 2018;121(Suppl. 3):28–32. DOI: 10.1111/bju.14145

11. Denton A.S., Clarke N., Maher J. Non-surgical interventions for late radiation cystitis in patients who have received radical radiotherapy to the pelvis. Cochrane Database Syst Rev 2002;2002:CD001773. DOI: 10.1002/14651858.CD001773

12. Kocherov A.A., Kocherova E.V. Use of URO-HYAL in treatment of constant dysuria in patients with chronic cystitis. Urologicheskie vedomosti = Urology Reports 2015;(1):103–4. (In Russ.).

13. Tararova E.A., Krupin V.N., Streltsova O.S. Dynamics of the mucosa condition during radiation treatment. Proceedings of the International Multidisciplinary Symposium “Chronic Pelvic Pain”. Nizhny Novgorod, June 16–17 2008. P. 23–27. (In Russ.).

14. Pan Y.T., Lavelle J.P., Bastacky S.I. et al. Detection of tumorigenesis in rat bladders with optical coherence tomography. Med Phys 2001;28(12):2432–49. DOI: 10.1118/1.141872

15. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022;72(1):7–33. DOI: 10.3322/caac.21708

16. Clinical guidelines. Cystitis in women. 2023. Available at: https://cr.minzdrav.gov.ru/. (In Russ.).

17. Kaprin A.D., Semin A.V., Kostin A.A. Effectiveness of Canephron N medication in oncological patients receiving radiation treatment on the pelvic organs. Russkiy Meditsinskiy Zhurnal = Russian Medical Journal 2007;15(4):18–22. (In Russ.).

18. Martov A.G., Ergakov D.V. Capabilities of using Canephron N medication in rehabilitation of patients after endoscopic surgeries. Effektivnaya farmakoterapiya = Effective Pharmacotherapy 2012;(42):44–51. (In Russ.).

19. Amdii R.E., Al-Shukri S.K., Kuzmin I.V. et al. Use of Canephron N in treatment of acute uncomplicated cystitis in women. UrologicheskieVedomosti 2016;(6):16–22.

20. Nausch B., Pace S., Pein H. et al. The standardized herbal combination BNO 2103 contained in Canephron® N alleviates inflammatory pain in experimental cystitis and prostatitis. Phytomedicine 2019;60:152987 DOI: 10.1016/j.phymed.2019.152987

21. Cox J.D., Stetz J., Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31(5):1341–6. DOI: 10.1016/0360-3016(95)00060-C